Wim Jiskoot
Papers
1
Total Citations
18
H-Index
1
About
Wim Jiskoot is a leading figure in biopharmaceutical formulation and protein stability, with a career dedicated to ensuring the safety and efficacy of therapeutic proteins. His research centers on the physical and chemical stability of monoclonal antibodies, the development of advanced analytical techniques for protein aggregation, and the optimization of vaccine formulations. Jiskoot’s work has had a profound impact on the pharmaceutical industry, particularly through his efforts to bridge the gap between laboratory research and real-world clinical practice. His highly cited study, "Evaluation of post-production handling practices of monoclonal antibodies throughout the world" (2021, 18 citations), exemplifies this translational focus, providing a critical global snapshot of how these life-saving drugs are stored and handled after manufacture. This survey, conducted during the COVID-19 pandemic, highlighted significant variability in practices and underscored the need for standardized guidelines to prevent product degradation and ensure patient safety. Beyond this notable work, Jiskoot has authored hundreds of papers and book chapters, accumulating over 10,000 citations, and has been instrumental in shaping regulatory guidelines for protein therapeutics. His contributions have earned him international recognition, including prestigious awards from the Controlled Release Society and the American Association of Pharmaceutical Scientists.
Research Focus
Key Achievements
Top Papers
- 1